Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447851 | 0.90 | ALDH1A1 (0.54) | ACACBALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL5449773 | 0.86 | PRMT5 (0.49) | ALDH1A1KMT2AMEN1POLBDRD2 | |
| SCHEMBL5451891 | 0.85 | MTNR1A (0.48) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL5456538 | 0.84 | NPC1 (0.67) | NPC1ALDH1A1KMT2AMEN1GFER | |
| SCHEMBL5453861 | 0.83 | DRD2 (0.48) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL5456171 | 0.83 | KMT2A (0.43) | ACACBALDH1A1KMT2AMEN1POLB | |
| SCHEMBL5460738 | 0.83 | CNR1 (0.51) | ACACBALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL5453473 | 0.82 | KMT2A (0.53) | ACACBALDH1A1KMT2AMEN1POLB | |
| SCHEMBL5753631 | 0.81 | DRD2 (0.53) | ACACBKMT2AMEN1POLBDRD2 | |
| SCHEMBL5447909 | 0.81 | DRD2 (0.45) | ALDH1A1KMT2AMEN1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | NPC1 608/4885ACACB 3033/4885ALDH1A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.